Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | GMNN | O75496 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 4/20 | 0.31 |
| ▸ | CES1 | P23141 | 4/20 | 0.31 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4048266 | 0.71 | — | — | |
| SCHEMBL6850245 | 0.70 | TSHR (0.40) | CES2THRBCTSLCTSBGMNN | |
| SCHEMBL28319692 | 0.69 | — | — | |
| SCHEMBL4601980 | 0.68 | TSHR (0.44) | CES2THRBCTSLCTSBGMNN | |
| SCHEMBL871631 | 0.68 | TSHR (0.44) | CES2THRBCTSLCTSBGMNN | |
| SCHEMBL2025361 | 0.67 | — | — | |
| SCHEMBL9887861 | 0.67 | — | — | |
| SCHEMBL27255307 | 0.67 | TSHR (0.44) | CES2THRBCTSLCTSBGMNN | |
| SCHEMBL28407024 | 0.67 | TSHR (0.44) | CES2THRBCTSLCTSBGMNN | |
| SCHEMBL28832704 | 0.67 | TSHR (0.44) | CES2THRBCTSLCTSBGMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040053923-A1 | Novel isoindole derivatives | BANYU PHARMACEUTICAL CO., LTD. | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053923-A1 | Novel isoindole derivatives | GPR119, SLC5A2, SLC5A1 | CES2 1817/4885THRB 3051/4885CTSL 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.